[Statistical analysis of recovery from sudden deafness among treatment groups].
This study examined 131 patients with idiopathic sudden deafness in whom the averaged of five frequency hearing levels was greater than 60dB. Since combined pharmacotherapy has been used in the treatment of idiopathic sudden deafness, it is hard to make a quantitative analysis of single-drug efficacy. We used a single-drug treatment in turn to assess the drug efficacy within 30 days after the onset. There was no significant difference among patients treated within 6 days and not less than 7 days after the onset with steroid therapy, PGE1 therapy, and defibrinogenation therapy. Similarly, there was no significant difference among patients treated within 6 days and not less than 7 days after the onset with steroid and defibrinogenation combined therapy, steroid and PGE1 combined therapy, and steroid, defibrinogenation and Lasix-Vitamin combined therapy. In case of no steroid effect, treatment with defibrinogenation, PGE1 and Lasix-Vitamin therapy could achieve hearing improvement.
Kitamura
K
K
Department of Otolaryngology, Osaka University Medical School.
Doi
K
K
Takeda
N
N
Mishiro
Y
Y
Okusa
M
M
Kubo
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage*; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000008:administration & dosage*; D006309:Hearing / Q000187:drug effects; D003639:Hearing Loss, Sudden / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013256:Steroids / Q000008:administration & dosage; D014815:Vitamins / Q000008:administration & dosage*
D013256:Steroids; D014815:Vitamins; D005665:Furosemide; D000527:Alprostadil